論文

査読有り
2019年5月

Gene expression profile of peripheral blood mononuclear cells may contribute to the identification and immunological classification of breast cancer patients.

Breast cancer (Tokyo, Japan)
  • Eiji Suzuki
  • Masahiro Sugimoto
  • Kosuke Kawaguchi
  • Fengling Pu
  • Ryuji Uozumi
  • Ayane Yamaguchi
  • Mariko Nishie
  • Moe Tsuda
  • Takeshi Kotake
  • Satoshi Morita
  • Masakazu Toi
  • 全て表示

26
3
開始ページ
282
終了ページ
289
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1007/s12282-018-0920-2
出版者・発行元
Springer Science and Business Media LLC

BACKGROUND: It has been reported that the gene expression profile of peripheral blood mononuclear cells (PBMCs) exhibits a unique gene expression signature in several types of cancer. In this study, we aimed to explore the breast cancer patient-specific gene expression profile of PBMCs and discuss immunological insight on host antitumor immune responses. METHODS: We comprehensively analyzed the gene expression of PBMCs by RNA sequencing in the breast cancer patients as compared to that of healthy volunteers (HVs). Pathway enrichment analysis was performed on MetaCoretm to search the molecular pathways associated with the gene expression profile of PBMCs in cancer patients compared with HVs. RESULTS: We found a significant unique gene expression signature, such as the Toll-like receptor (TLR) 3- and TLR4-induced Toll/interleukin-1 receptor domain-containing adapter molecule 1 (TICAM1)-specific signaling pathway in the breast cancer patients as compared to that of healthy volunteers. Distinctive immunological gene expression profiles also showed the possibility of classifying breast cancer patients into subgroups such as T-cell inhibitory and monocyte-activating groups independent of known phenotypes of breast cancer. CONCLUSIONS: These preliminary findings suggest that evaluation of gene expression patterns of PBMCs might be both a less invasive diagnostic procedure and a useful way to reveal immunological insight of breast cancer, including biomarkers for cancer immunotherapy, such as immune checkpoint inhibitor therapy.

リンク情報
DOI
https://doi.org/10.1007/s12282-018-0920-2
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/30317464
URL
http://www.scopus.com/inward/record.url?eid=2-s2.0-85055283218&partnerID=MN8TOARS
Scopus Citedby
https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85055283218&origin=inward
ID情報
  • DOI : 10.1007/s12282-018-0920-2
  • ISSN : 1340-6868
  • eISSN : 1880-4233
  • ORCIDのPut Code : 69305201
  • PubMed ID : 30317464
  • SCOPUS ID : 85055283218

エクスポート
BibTeX RIS